BARCELONA, Spain — In this Healio Video Perspective from the Euretina congress, Gemmy Cheung, MD, PhD, expresses satisfaction with the effects of sozinibercept in patients with polypoidal choroidal vasculopathy, or PCV.
In a phase 2b study, sozinibercept (Opthea) administered in combination with ranibizumab showed superior outcomes compared with ranibizumab monotherapy in the overall population of patients with neovascular age-related macular degeneration.
“In particular, what is very exciting for me is that in the PCV subgroup of patients we saw a marked improvement in visual